Blood Flow Restriction-Low Intensity Resistance Training (BFR-LIRT) for Arm Paresis Post-stroke
NCT07925541, Not applicable, Not yet recruiting, University of Maryland, Baltimore
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Blood Flow Restriction-Low Intensity Resistance Training (BFR-LIRT) for Arm Paresis Post-stroke | ClinicalTrials.gov |
| NCT number | NCT07925541 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 32 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Maryland, Baltimore | ClinicalTrials.gov |
| Conditions | Hemiparesis of the Upper Limb Following Stroke | ClinicalTrials.gov |
| Interventions | Blood flow restriction with low intensity resistance training, Sham Blood flow restriction with low intensity resistance training | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Upper Extremity Muscle Strength | Baseline and after 3, 6, and 8 weeks of intervention commencement | Upper extremity muscle strength will be quantified as active peak joint torque of the paretic shoulder abductors, elbow extensors, wrist flexors, and wrist extensors during concentric contractions with upper extremity hemiparetic attachments. Changes in muscle strength will be compared between the BFR-LIRT and Sham+LIRT groups over the intervention period. | ClinicalTrials.gov |
| Secondary | Reach-to-Grasp Movement Time | Baseline and after 3, 6, and 8 weeks of intervention commencement | Reach-to-grasp performance of the paretic upper extremity will be recorded using a 3-dimensional motion-tracking system. Participants will reach from a standardized starting position and grasp a dowel placed at 90% of their individual maximum reaching distance. Total movement time will be calculated from movement onset to successful grasp of the object. Shorter movement time indicates improved reaching performance. | ClinicalTrials.gov |
| Secondary | Reach Path Curvature | Baseline and after 3, 6, and 8 weeks of intervention commencement | Reach path curvature will be measured during the same reach-to-grasp task using 3-dimensional motion tracking. Curvature will be calculated as the deviation of the wrist trajectory from a straight path between movement onset and object grasp. Lower values indicate a straighter and more direct reaching movement. | ClinicalTrials.gov |
| Secondary | Upper Extremity Motor Impairment | Baseline and after 3, 6, and 8 weeks of intervention commencement | Upper extremity motor impairment will be assessed using the Upper Extremity Fugl-Meyer Assessment (UEFM), a standardized clinical measure of motor impairment after stroke. Higher scores indicate less upper extremity motor impairment. | ClinicalTrials.gov |
| Other | Corticospinal Excitability | Baseline and after 3, 6, and 8 weeks of intervention commencement | Corticospinal excitability of the paretic extensor carpi radialis longus (ECRL) will be assessed using transcranial magnetic stimulation (TMS). A TMS recruitment curve will be generated by stimulating the ipsilesional motor cortex at increasing stimulation intensities. Corticospinal excitability will be quantified using the slope of the fitted recruitment curve. A steeper recruitment curve reflects greater corticospinal excitability. | ClinicalTrials.gov |
| Other | Corticoreticulospinal Pathway Excitability | Baseline and after 3, 6, and 8 weeks of intervention commencement | Corticoreticulospinal pathway excitability will be assessed using TMS delivered over the motor cortex contralateral to the paretic arm while recording ipsilateral motor-evoked potentials from the paretic ECRL. Excitability will be quantified using the normalized area of the ipsilateral motor-evoked potential response. Greater response area indicates greater excitability of this pathway. | ClinicalTrials.gov |
| Other | Spinal Segmental Excitability | Baseline and after 3, 6, and 8 weeks of intervention commencement | Spinal segmental excitability will be assessed using the H-reflex recorded from the paretic ECRL during peripheral stimulation of the radial nerve. The maximum H-reflex response will be normalized to the maximum motor response and expressed as the Hmax/Mmax ratio. This measure will be used to quantify changes in spinal pathway excitability. | ClinicalTrials.gov |
| Other | Cross-Sectional Area of the Extensor Carpi Radialis Longus Muscle | Baseline and after 3, 6, and 8 weeks of intervention commencement | Muscle size will be assessed using B-mode ultrasound to measure the cross-sectional area of the paretic extensor carpi radialis longus muscle. Three measurements will be obtained using standardized arm and probe positioning, and the average cross-sectional area will be used for analysis. Greater cross-sectional area indicates greater muscle size. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)